Celiac disease is far more than a digestive condition — it is a systemic autoimmune disorder driven by a precise immunological cascade that destroys the small intestinal lining and blocks nutrient absorption across the board. It is also one of the most underdiagnosed conditions in medicine, with an estimated 83% of affected individuals undiagnosed or misdiagnosed for an average of 6–10 years. This article covers the full clinical picture: the immunological mechanism, villous atrophy staging, the full spectrum of presentation, what testing actually measures, and a complete integrative management protocol.
What Is Celiac Disease?
Celiac disease is a systemic autoimmune disorder in which the ingestion of gluten — a composite of storage proteins (gliadins and glutenins) found in wheat, barley, and rye — triggers an aberrant immune response in genetically susceptible individuals. This immune response targets the small intestinal lining, causing progressive destruction of the villi — the finger-like projections responsible for the majority of nutrient absorption.
Celiac disease affects approximately 1% of the global population — roughly 3 million Americans — but population screening studies consistently identify a 5:1 ratio of undiagnosed to diagnosed cases. The condition is associated with HLA-DQ2 (present in ~90% of celiac patients) and HLA-DQ8 (~5–10%) genetic markers, though these are necessary but not sufficient — approximately 30–40% of the general population carries these alleles without developing celiac disease. Environmental triggers, gut permeability, and the intestinal microbiome appear to determine whether genetically susceptible individuals develop active disease.
The Immunological Mechanism: How Gluten Triggers Autoimmunity
The celiac disease cascade is one of the best-characterized autoimmune mechanisms in medicine — a precise, multi-step immunological process initiated by a single dietary protein:
- Gluten reaches the small intestine: Gluten peptides — particularly α-gliadin — resist complete digestion by gastric acid and pancreatic proteases due to their unusually high proline and glutamine content. Proline-rich sequences cannot be cleaved by human digestive enzymes, leaving immunogenic peptide fragments (particularly the 33-mer α-gliadin peptide) intact in the small intestinal lumen
- Epithelial crossing: Intact gliadin peptides cross the intestinal epithelium via transcytosis and by triggering zonulin-mediated tight junction opening — increasing intestinal permeability and enabling paracellular passage of antigenic material into the lamina propria. Dr. Alessio Fasano's discovery that gliadin directly triggers zonulin release provided the molecular mechanism linking gluten to intestinal permeability (Fasano, Annals of the New York Academy of Sciences, 2012)
- Deamidation by tissue transglutaminase 2 (tTG2): In the lamina propria, the enzyme tissue transglutaminase 2 deamidates glutamine residues in gliadin peptides — converting them to glutamate. This modification dramatically increases their binding affinity to HLA-DQ2/DQ8 molecules on antigen-presenting cells (APCs), making them highly immunogenic
- Adaptive immune activation: Deamidated gliadin peptides are presented by HLA-DQ2/DQ8 on APCs to CD4+ T-helper cells in the lamina propria, triggering a robust Th1 inflammatory response with release of interferon-gamma (IFN-γ), TNF-α, and IL-15 — cytokines that drive enterocyte apoptosis and recruit intraepithelial lymphocytes (IELs)
- Autoantibody production: Activated B cells produce IgA and IgG antibodies against tTG2 (anti-tTG IgA — the primary diagnostic marker), deamidated gliadin peptides (DGP antibodies), and endomysium (EMA). These autoantibodies are diagnostically useful but also drive tissue damage — tTG2 is expressed throughout the body, explaining celiac's systemic manifestations
- Innate immune amplification: IL-15 activates intraepithelial CD8+ T-lymphocytes and NK cells, which directly kill enterocytes — creating a second wave of mucosal destruction that proceeds independently of gluten exposure once activated
- Villous destruction: The combined effect of cytokine-driven apoptosis, IEL-mediated cytotoxicity, and ongoing inflammation progressively destroys the villous architecture — producing the histological pattern of villous atrophy and crypt hyperplasia that defines celiac disease
Villous Atrophy & the Marsh Classification
The degree of intestinal damage in celiac disease is staged by the Marsh-Oberhuber classification, which guides both diagnosis and monitoring of recovery:
- Marsh 0: Normal intestinal histology — no celiac changes
- Marsh 1: Increased intraepithelial lymphocytes (>25 IELs per 100 enterocytes) — earliest detectable change; villi intact. Can be seen in latent celiac disease, gluten sensitivity, H. pylori infection, and NSAID use
- Marsh 2: Elevated IELs plus crypt hyperplasia — crypts deepen as the intestine attempts compensatory regeneration; villi still present but altered
- Marsh 3a: Partial villous atrophy — villi shortened but present; significant malabsorption begins
- Marsh 3b: Subtotal villous atrophy — villi markedly reduced; substantial malabsorption across all nutrient classes
- Marsh 3c: Total villous atrophy — complete flattening of the mucosal surface; profound malabsorption; highest risk for complications
A fully atrophied small intestinal lining loses up to 90% of its absorptive surface area. Every nutrient class is affected — proteins, fats, carbohydrates, fat-soluble vitamins, B vitamins, iron, calcium, magnesium, zinc, and selenium.
Clinical Presentation: The Full Spectrum
Celiac disease is vastly underdiagnosed in part because its presentation is highly variable — the "classic" picture of diarrhea and weight loss represents only a minority of cases:
Classic GI Presentation
- Chronic or recurrent diarrhea — often fatty, malodorous, and voluminous
- Abdominal distension and bloating
- Steatorrhea (fatty stools)
- Weight loss despite adequate caloric intake
- Nausea and vomiting
Atypical & Extraintestinal Manifestations
The majority of celiac patients present with atypical or primarily extraintestinal symptoms — reflecting the systemic distribution of tTG2 and the downstream consequences of malabsorption:
- Iron-deficiency anemia: The most common atypical presentation — iron absorption occurs in the proximal small intestine (duodenum and jejunum), precisely where villous atrophy is most severe
- Osteoporosis & fractures: Calcium and vitamin D malabsorption drives bone loss — celiac disease is an independent risk factor for osteoporotic fracture, even in young adults
- Neurological manifestations: "Gluten ataxia" (cerebellar ataxia), peripheral neuropathy, epilepsy, and cognitive dysfunction — mediated by anti-tTG6 antibodies and direct neuroinflammation. Dr. Marios Hadjivassiliou at Sheffield Teaching Hospitals has published extensively on neurological celiac disease as a distinct clinical entity (Hadjivassiliou et al., The Lancet Neurology, 2010)
- Dermatitis herpetiformis (DH): The skin manifestation of celiac disease — intensely pruritic, vesicular rash on the elbows, knees, and buttocks. IgA deposits in the skin; responds to gluten-free diet and dapsone
- Infertility & pregnancy complications: Untreated celiac disease is associated with recurrent miscarriage, intrauterine growth restriction, and infertility in both men and women
- Liver disease: Elevated transaminases ("celiac hepatitis") resolves on a gluten-free diet in most cases; untreated celiac is associated with increased risk of autoimmune hepatitis
- Thyroid autoimmunity: Hashimoto's thyroiditis co-occurs with celiac at significantly elevated rates — sharing HLA haplotypes and potentially driven by molecular mimicry between gliadin epitopes and thyroid antigens
- Type 1 diabetes: 5–10% of Type 1 diabetics have celiac disease — sharing HLA-DQ2/DQ8 and autoimmune mechanisms
- Recurrent aphthous ulcers, enamel defects, delayed puberty, short stature, and psychiatric symptoms round out the broad atypical spectrum
Diagnosis: What the Tests Actually Measure
Serology
- Anti-tTG IgA: The primary screening test — sensitivity 95%, specificity 95% in patients with normal total IgA. False negatives occur in IgA deficiency (present in 2–3% of celiac patients) and with severe villous atrophy (which reduces IgA-producing plasma cells)
- Total serum IgA: Must be ordered alongside anti-tTG IgA — IgA deficiency produces false-negative anti-tTG results
- Anti-tTG IgG & deamidated gliadin peptide (DGP) IgG: Used when IgA deficiency is confirmed
- Endomysial antibody (EMA) IgA: Highly specific (>99%) — used as confirmatory test; requires immunofluorescence and is operator-dependent
- Deamidated gliadin peptide (DGP) IgA/IgG: More sensitive than older native gliadin antibody tests; useful in young children and IgA-deficient patients
Critical note: Serology must be performed while the patient is consuming a normal gluten-containing diet — a gluten-free diet prior to testing will normalize antibodies and produce false negatives. Patients who have already eliminated gluten require a gluten challenge (typically 3–10g gluten daily for 6–8 weeks) before reliable serological or histological assessment.
Small Intestinal Biopsy
Duodenal biopsy via upper endoscopy remains the gold standard for celiac diagnosis — confirming villous atrophy and Marsh staging. Multiple biopsies (≥4) from the second and third portions of the duodenum are required, as patchy involvement can produce sampling error.
Genetic Testing (HLA-DQ2/DQ8)
Negative HLA-DQ2/DQ8 effectively excludes celiac disease (>99% negative predictive value) — useful for ruling out celiac in patients already on a gluten-free diet or in first-degree relatives of celiac patients. Positive HLA typing confirms susceptibility but not disease — requires serological and/or histological confirmation.
Point-of-Care Testing
Fingerstick anti-tTG IgA tests are now available for rapid screening — useful in primary care and remote settings, though laboratory confirmation is required before diagnosis.
Integrative Management Protocol
The Strict Gluten-Free Diet — Non-Negotiable
The gluten-free diet (GFD) is the only evidence-based treatment for celiac disease — and it must be strict, not merely reduced. Even 50mg of gluten daily (approximately 1/100th of a slice of bread) is sufficient to maintain intestinal inflammation and prevent villous recovery in sensitive individuals (Catassi et al., American Journal of Clinical Nutrition, 2007).
- Eliminate all wheat, barley, rye, and contaminated oats
- Dedicated gluten-free cooking equipment, toasters, cutting boards — cross-contamination at the parts-per-million level causes ongoing mucosal damage
- Label scrutiny: "wheat-free" ≠ gluten-free; malt, malt vinegar, brewer's yeast, and hydrolyzed wheat protein all contain gluten
- Medications, supplements, communion wafers, and lip products can be hidden sources
- Work with a registered dietitian specializing in celiac disease for the first 12 months
Monitor for Nutritional Deficiencies
At diagnosis and periodically during recovery, assess and replicate:
- Iron & ferritin — the most commonly deficient nutrient at diagnosis
- Vitamin D & calcium — DEXA scan to assess bone density at diagnosis
- Vitamin B12 & folate — B12 absorption at the terminal ileum is frequently impaired
- Zinc — absorbed in the proximal small intestine; commonly depleted in active celiac
- Magnesium — profound deficiency in severe villous atrophy
- Fat-soluble vitamins (A, E, K) — secondary to fat malabsorption
Support Intestinal Healing
- Digestive enzymes: Broad-spectrum enzymes support digestion during mucosal recovery — particularly lipase and protease to reduce undigested food antigen burden while the gut heals
- L-Glutamine (5–15g daily): The primary enterocyte fuel — supports villous regrowth and tight junction restoration
- Zinc carnosine: Clinically validated for mucosal repair and tight junction stabilization
- Vitamin D3 + K2: Dual role — bone repletion and immune modulation (vitamin D deficiency impairs regulatory T-cell function, perpetuating autoimmunity)
- Probiotics: Lactobacillus rhamnosus GG and Bifidobacterium species support microbiome restoration and mucosal immune balance during recovery
- Bone broth & collagen peptides: Glycine and proline support the structural repair of the intestinal epithelium
Address Co-existing Conditions
- SIBO: Highly prevalent in celiac disease — both as a cause of non-responsive celiac symptoms and as a consequence of villous atrophy-related dysmotility. Screen with breath testing if symptoms persist on a strict GFD
- Microscopic colitis: Co-occurs with celiac at elevated rates — consider colonoscopy if diarrhea persists despite GFD adherence
- Lactose intolerance: Secondary to brush border lactase loss — typically resolves with mucosal healing but may require temporary dairy restriction during recovery
- Thyroid autoimmunity: Screen for Hashimoto's at diagnosis; monitor TSH annually
- Bone density: DEXA scan at diagnosis; repeat at 1–2 years on GFD to confirm recovery
Monitoring Response to Treatment
- Anti-tTG IgA should normalize within 6–12 months of strict GFD — persistent elevation indicates ongoing gluten exposure or refractory celiac disease
- Repeat duodenal biopsy at 12–24 months on GFD confirms histological recovery — villous healing lags behind serological normalization by months to years
- Persistent symptoms on strict GFD require evaluation for SIBO, microscopic colitis, refractory celiac disease (RCD), or inadvertent gluten exposure